Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel
- 99 Downloads
Gemcitabine/docetaxel (G/D) combination therapy has shown favourable response rates in patients with leiomyosarcoma (LMS) [1, 2, 3]. Although, G/D treatment is generally well tolerated, it can cause side effects, such as myelosuppression and fatigue.
We describe two out of nine patients with advanced LMS, refractory to doxorubicin who developed acute pulmonary toxicity after treatment with 3-weekly gemcitabine 900 mg/m2 as 90-min infusion on day 1 and 8 followed by docetaxel 100 mg/m2 as 60-min infusion on day 8 and s.c. pegfilgrastim on day 9.
KeywordsPulmonary toxicity Gemcitabine Docetaxel Leiomyosarcoma
- 2.Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS, Lee JS, Couwlier C, Palazzolo K, Baker LH (2004) Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 22:1706–1712PubMedCrossRefGoogle Scholar
- 3.Bay JO, Ray-Coquard I, Fayette J, Leyvraz S, Cherix S, Piperno-Neumann S, Chevreau C, Isambert N, Brain E, Emile G, Le Cesne A, Cioffi A, Kwiatkowski F, Coindre JM, Bui NB, Peyrade F, Blay JY (2006) Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer 119:706–711PubMedCrossRefGoogle Scholar
- 4.Kouroussis C, Mavroudis D, Kakolyris S, Voloudaki A, Kalbakis K, Souglakos J, Agelaki S, Malas K, Bozionelou V, Georgoulias V (2004) High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Lung Cancer 44:363–368PubMedCrossRefGoogle Scholar